An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Objectives: The objective of this study will be to determine the safety, tolerability, drug
blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily
compared with placebo in patients with mild to moderate Dementia of the Alzheimer's Type.